NCT06820294Enrolling by invitation
Retrospective WGS Study
Assessing the Clinical Benefits of Whole Genome Sequencing for Children With Neoplasms
Source: ClinicalTrials.gov · Last updated 11 Feb 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This retrospective case series reviews clinical notes to assess whether NHS whole genome sequencing provides tangible benefits for paediatric tumours.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 2000 (estimated)
- First submitted
- 5 Feb 2025
- Start date
- 22 Sept 2022
- Primary completion date
- 31 Mar 2027
- Lead sponsor
- The Wellcome Sanger Institute
- Diseases
- Childhood cancers
- NCT number
- NCT06820294
What you commit to
- Study type: Observational
- Planned participants: 2000
- From 22 Sept 2022 to the primary completion date, 31 Mar 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Individuals without a neoplastic disorder.
Age
- Individuals beyond the age of 21
Other
- Anyone not offered NHSE whole genome sequencing
Who the study is looking for
- All children and young people (up to the age of 21 years) diagnosed with a neoplastic disorder who have been offered NHSE whole genome sequencing.
Age in the registry: 0 years to 21 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Wellcome Sanger Institute Coordinator of this site? Confirm its status | Cambridge | United Kingdom | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.